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Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600
million people infected and 800 million, mostly children, at risk of contracting the disease following
infection predominantly with Schistosoma mansoni, Schistosoma haematobium, or Schistosoma
japonicum. The disease burden is estimated to exceed 70 million disability-adjusted life-years, and
leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people
with schistosomiasis are highly susceptible to malaria, tuberculosis, and hepatic and acquired
immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment
and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population
has received the drug, and those treated are at continuous risk of reinfection necessitating repeated
drug administration and the emergence of drug-resistant parasites is a constant threat (1). Currently
there is no vaccine. The a priori requirements for discovery of a vaccine formulation include the
following: identification of protective key immune players in humans; characterization and isolation
of target antigens; establishment of efficacy in terms of reduction of parasite burden as well as
amelioration of immunopathology; establishment of safety; and finally, provision of considerable
funds along with physical infrastructure and qualified personnel to carry out clinical trials.
The target of >40% protection has been achieved with some schistosome molecules such as
fatty acid binding protein (Sm14), paramyosin, calpain large subunit (Sm80), superoxide dismutase
(SOD), glutathione S-transferase (GST), glyceraldehyde 3-phosphate dehydrogenase, and cysteine
peptidases (2). Furthermore, Pearson et al. (3) identified the antigens selectively recognized by
serum IgG1 and IgE of S. haematobium patients who acquired praziquantel-induced resistance
(DIR) to the infection, or self-cured macaques following S. japonicum infection. The probed
antigens were derived from S.mansoni and S. japonicum, likely because of the documented antigen
conservation among the three main clinically important species, and were selected among those
known to be secreted or localized to the tegument. The tegument is at the host–parasite interface,
but its access by host effector antibodies is entirely prevented in healthy schistosomes, otherwise
they would not survive a day, not to mention decades, in the host bloodstream. Anyhow, the
study identified once again calpain, SOD, and GST as vaccine candidates together with surface
membrane-associated antigens such as tetraspanins and glucose transporters, as well as an array
of newly discovered target antigens. A remarkable finding in the study was the implication that
type 2 (IgG1 and IgE) and not type 1-related antibodies are critical for human resistance against S.
haematobium reinfection. Besides the worm tegument, which may not be accessed by host effector
antibodies, the digestive tract is the other major interface between host and parasite. Schistosome
peptidases responsible for digesting blood-born cells, components, and nutrients may be targeted,
and possibly neutralized and blocked, by host antibodies and, thus, represent potential vaccine
candidates. The timely study of Figueiredo et al. (4) reviewed what is known about the properties
and vaccine potential of proteins secreted by the esophagus, and the lining (gastrodermis) of the
blind-ended gut, namely Sm14, Sm10.3, venom allergen-like (VAL) protein, Cu–Zn SOD, cathepsin
B, and cathepsin L.
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It is reassuring we have convened on a handful of promising
vaccine candidates and several reviews in this issue illustrate
the advances that have been made. Kurtis et al. (5) reviewed
the discovery, gene cloning, and expression of paramyosin; its
localization in muscles, just below the tegument, and in the gut
lining of adult worms; its protective potential in rodents against
S. mansoni (24–53% protection without adjuvant, associated with
induction of interferon-gamma, IFN-γ) and against S. japon-
icum (62–86% protection without adjuvant); its immunogenic-
ity in humans, whereby S. japonicum paramyosin was found to
be the target of protective type 2-biased cytokine and antibody
responses; and plans to move it toward phase I clinical trials. The
history of the discovery, gene cloning and expression trials, vac-
cine potential, and outcomes of completed phase I clinical trials
were reported for the fatty acid binding protein, Sm14, by Tendler
et al. (6). Cost-effective, large-scale production of recombinant
Sm14 expressed in Pichia pastoris is currently in place, and the
protein will be formulated with glucopyranosyl lipid adjuvant-
stable emulsion (GLA-SE) adjuvant. This synthetic adjuvant has
been selected as it enhances type 1, namely IFN-γ, responses,
identified as the basis of the Sm14-mediated protective immunity
in animal models and humans. The protective potential of other
prominent vaccine candidates, the antioxidant enzymes Cu–Zn
SOD and glutathione S peroxidase formulated as plasmid cDNA
and recombinant protein preparations, has been assessed in the
Olive Baboon (7). The vaccine formulations were entirely safe
and strongly immunogenic but, in accord with a plethora of pre-
vious vaccine trials involving type 1 immune response-inducing
adjuvants or plasmid cDNA constructs, induced limited and/or
variable protection in non-human primates against S. mansoni
challenge infection.
Despite the fact that protective immunity to S. mansoni and S.
haematobium infection in humans is documented to be depen-
dent on type 2 immune responses (2, 3, 5, and references
therein), formulations of schistosomiasis vaccines destined for
use in humans still aim to induce predominant type 1-related
cytokines and antibodies, clearly indicating we have not yet
reached a consensus regarding the type of immune responses an
anti-schistosomiasis vaccine should elicit. The review by Fonseca
et al. (8) is, thus, particularly well timed as it seeks to find the
optimal immune weapons generating vaccination-mediated resis-
tance against schistosome infection via identifying the immune
responses associated with protective immunity elicited by sev-
eral vaccine candidates namely GST, Sm14, calpain (Sm80),
tetraspanins, and Sm29 in mono- and multivalent formulations.
The review emphasized and documented the importance of spe-
cific antibodies and strong IFN-γ production in parasite elimina-
tion regardless of the vaccine candidate used.
Since currently available vaccine candidate formulations medi-
ate type 1-biased protective immunity, which is limited or partial
at best, it is important to revisit the lessons of the radiation-
attenuated (RA) cercarial vaccine (9). In this respect, a meta-
analysis of the experimental studies undertaken with the RA
cercarial vaccine in mice (755 observations from a total of 105
articles) was performed by Fukushige et al. (10), who reported
that the RA vaccine has the potential to induce protection as high
as 78% with a single dose of vaccine. While major predictors of
protection were the immunizing cercarial number (antigen dose)
and interval between the last vaccination and challenge (duration
of immune memory), the study emphasized the importance of
host immunization with more than a single schistosomemolecule
in order to achieve protection. The early pioneers studying schis-
tosome biology helped devise an efficacious schistosomiasis vac-
cine by demonstrating that the physiological and reproductive
status of S. mansoni is strongly influenced by the microenviron-
ment of the host and that the lung and liver are the sites of innate
and acquired immunity-mediated parasite attrition in permissive
(mice, hamsters) and non-permissive (rats) hosts (11).
To compile a road map for the successful development of a
schistosomiasis vaccine: (1) It appears we have at hand a plethora
of well-characterized, ready for use vaccine candidates (2–11).
(2) As noted by Fonseca et al. (8), 24 h and older schistosomula
are refractory to killing by antibody-dependent complement-
mediated attrition, and this fully applies to antibody-dependent
cell-mediated cytotoxicity (ADCC) as well. (3) Specific antibodies
may access the worm gut lumen and those that escape immediate
digestion might be able to neutralize and interfere with enzymes
critical for worm feeding and fecundity, but not survival, as these
processes by definition impact on juvenile and adult worms not
schistosomula migrating in the lung capillaries and liver sinusoids
(4). (4) We are left then with the hunt and chase theory, whereby
immune antibodies and cells interact with excreted–secreted par-
asite products in the vicinity ofmigrating schistosomula, alarming
and activating effector immune cells (2, 9, 12). (5) Eosinophils
and basophils would be particularly effective immune cells but
need a type 2 immune environment for recruitment and activation
(2, 9, 12, 13). (6) Protective immunity against reinfection with
S. mansoni and S. haematobium in humans is documented to be
associated with type 2 responses (2, 3, 5, 8). (7) There is consider-
able evidence demonstrating that immunization of outbred, akin
toman,mice with selected vaccine candidates in conjunction with
type 2 immune response-inducing cysteine peptidase, papain,
or cytokines (namely interleukin-25, interleukin-33, or thymic
stromal lymphopoietin) can elicit a reduction in S. mansoniworm
burdens consistently higher than 50% and reaching the 78% level
achieved by vaccination with the RA cercarial vaccine (14). (8)
These molecules inducing type 2 immunity were replaced by S.
mansoni cysteine peptidases, leading to consistent and highly sig-
nificant (P< 0.0001) 50–83% protection of outbred mice against
S. mansoni challenge infection (15). (9) It has been demonstrated
that this approach, incorporating a cysteine peptidase-based vac-
cine, is effective in protecting hamsters andmice against S. haema-
tobium as well (16). (10) A consensus should be reached without
delay in order that independent, collaborative experiments could
be devised and undertaken that would result in the development
of a near sterilizing protective immunity-inducing schistosomiasis
vaccine (2, 9).
In conclusion, discovery of a successful vaccine for a host as
complex as man against a parasite as complex as Schistosoma is a
monumental scientific challenge withmany factors at play includ-
ing parasite strain; intensity, duration, and frequency of infection;
genetic make-up and immunological status of the host; perinatal
sensitization; host nutritional status; and co-infections with other
infectious pathogens. Insights of protective immune responses
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3902
El Ridi et al. Road to schistosomiasis vaccine development
generated by vaccination have been deduced from experiments
with rodents or, more importantly, non-human primates, but data
and experience with humans are still much needed. Important
considerations such as vaccine efficacy, safety, and cost, all count
in the development of a successful human vaccine. It is highly
unlikely that the vaccine, when available, would stand alone, but
it could be a major element in an integrated control package. A
primary goal should be the vaccination of children in endemic
regions at an age as early as possible on the path to the elimination
of schistosomiasis.
References
1. Ross AG, Olveda RM, Chy D, Olveda DU, Li Y, Harn DA, et al. Can mass drug
administration lead to the sustainable control of schistosomiasis? J Infect Dis
(2015) 211:283–9. doi:10.1093/infdis/jiu416
2. Othman A, El Ridi R. Schistosomiasis. In: Bruschi F, editor.Helminth Infections
and Their Impact on Global Public Health. New York: Springer (2014). p. 49–92.
3. Pearson MS, Becker L, Driguez P, Young ND, Gaze S, Mendes T, et al. Of
monkeys andmen: immunomic profiling of sera from humans and non-human
primates resistant to schistosomiasis reveals novel potential vaccine candidates.
Front Immunol (2015) 6:213. doi:10.3389/fimmu.2015.00213
4. Figueiredo BC, Ricci ND, de Assis NR, de Morais SB, Fonseca CT, Oliveira SC.
Kicking in the guts: Schistosoma mansoni digestive tract proteins are potential
candidates for vaccine development. Front Immunol (2015) 6:22. doi:10.3389/
fimmu.2015.00022
5. Kurtis JD, Jiz MA, Wu H, Olveda R, Jarilla B. Development of paramyosin as
a vaccine candidate for schistosomiasis. Front Immunol (2015) 6:347. doi:10.
3389/fimmu.2015.00347
6. Tendler M, Almeida M, Simpson A. Development of the Brazilian anti schisto-
somiasis vaccine based on the recombinant fatty acid binding protein Sm14 plus
GLA-SE adjuvant. Front Immunol (2015) 6:218. doi:10.3389/fimmu.2015.00218
7. Carvalho-Queiroz C, Nyakundi R, Ogongo P, Rikoi H, Egilmez NK, Farah IO,
et al. Protective potential of antioxidant enzymes as vaccines for schistosomiasis
in a non-human primate model. Front Immunol (2015) 6:273. doi:10.3389/
fimmu.2015.00273
8. Fonseca CT, Oliveira SC, Alves CC. Eliminating schistosomes through vac-
cination: what are the best immune weapons? Front Immunol (2015) 6:95.
doi:10.3389/fimmu.2015.00095
9. El Ridi R, Tallima H. Why the radiation-attenuated cercarial immunization
studies failed to guide the road for an effective schistosomiasis vaccine: a review.
J Adv Res (2015) 6:255–67. doi:10.1016/j.jare.2014.10.002
10. Fukushige M, Mitchell KM, Bourke CD, Woolhouse ME, Mutapi FA. Meta-
analysis of experimental studies of attenuated Schistosoma mansoni vaccines in
the mouse model. Front Immunol (2015) 6:85. doi:10.3389/fimmu.2015.00085
11. Knopf PM, Suri PB. S. mansoni trapping in lungs contributes to resistance to
reinfection. Front Immunol (2015) 6:186. doi:10.3389/fimmu.2015.00186
12. von Lichtenberg F, Sher A, McIntyre SA. Lung model of schistosome immunity
in mice. Am J Pathol (1977) 87:105–23.
13. Lichtenberg F, Sher A, Gibbons N, Doughty BL. Eosinophil-enriched inflam-
matory response to schistosomula in the skin of mice immune to Schistosoma
mansoni. Am J Pathol (1976) 84:479–500.
14. El Ridi R, Tallima H. Vaccine-induced protection against murine schistoso-
miasis mansoni with larval excretory-secretory antigens and papain or type-2
cytokines. J Parasitol (2013) 99:194–202. doi:10.1645/GE-3186.1
15. El Ridi R, Tallima H, Selim S, Donnelly S, Cotton S, Gonzales Santana B, et al.
Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity. PLoS
One (2014) 9(1):e85401. doi:10.1371/journal.pone.0085401
16. Tallima H, Dalton JP, El Ridi R. Induction of protective immune responses
against Schistosomiasis haematobium in hamsters and mice using cysteine
peptidase-based vaccine. Front Immunol (2015) 6:130. doi:10.3389/fimmu.
2015.00130
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 El Ridi, Othman and McManus. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3903
